MYRIAD GENETICS INC
Close on Oct 19, 2026
- Market cap
- $399.11M
- P/E (TTM)
- –
- Dividend yield
- –
About Myriad Genetics
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to assess disease risk, guide treatment decisions, and provide prenatal insights. The business focuses on three main segments: oncology, women's health, and mental health. Key products include hereditary cancer panels such as MyRisk, companion diagnostics like BRACAnalysis CDx and MyChoice CDx, tumor profiling assays including Prolaris, prenatal screens such as Prequel and Foresight, and pharmacogenomic tests like GeneSight. Its customers include patients, healthcare providers, health systems, and biopharmaceutical partners.
The company employs approximately 2,700 full-time equivalent staff and operates next-generation laboratory facilities. It sells its products directly through commercial teams in the United States and Japan, while serving broader international markets across Europe and the Asia-Pacific region via indirect channels and partnerships. The provided text does not disclose the company's headquarters location.
Summary of the business section of Myriad Genetics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MYRIAD GENETICS INC
- Founded
- 1992
- Headquarters
- Salt Lake City, UT
- Address
- 322 North 2200 West 84116
- Phone
- (801) 584-3600
- Website
- myriad.com
- Employees
- 2,700, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Salt Lake City, Utah
Stock & identifiers
- Ticker
- MYGN
- Exchange
- Nasdaq
- IPO date
- Oct 6, 1995
- Shares outstanding
- 96M, Jul 28, 2026
- Public float
- $494.05M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 2-for-1, Mar 26, 2009; 2-for-1, Sep 12, 2000
- SEC CIK
- 899923
- CUSIP
- 62855J104
- ISIN
- US62855J1043
- LEI
- 52990044IHUOUMETT163
- EIN
- 87-0494517
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Samraat S. Raha | President and CEO, Director | 1,068,083 |
| Paul J. Diaz | President and CEO, Director | 891,844 |
| Benjamin Richard Wheeler | Chief Financial Officer | 287,193 |
| Brian J. Donnelly | Chief Commercial Officer | 573,363 |
| Vishal Sikri | EVP, Commercial | 93,493 |
| Jennifer Lynne Fox | Chief Legal Officer | 305,964 |
| Raj Jampa | Chief Technology Officer | 251,889 |
| Mark Verratti | Chief Operating Officer | 629,646 |
| Dale Muzzey | Chief Scientific Officer | 326,310 |
| Kevin Richard Haas | Chief Technology Officer | 188,404 |
| Shereen Solaiman | Chief People Officer | 267,801 |
| Margaret Ancona | EVP, Strategy & Transformation | 127,726 |
| Natalie Munk | Chief Accounting Officer | 45,167 |
| Scott J. Leffler | Chief Financial Officer | 218,393 |
| Daniel Skovronsky | Director | 195,507 |
| Rashmi Kumar | Director | 171,889 |
| S. Louise Phanstiel | Director | 374,771 |
| Paul Bisaro | Director | 157,142 |
| Colleen F. Reitan | Director | 152,030 |
| Lee Nisley Newcomer | Director | 191,842 |
| Mark Steven Davis | Director | 106,665 |
| Heinrich Dreismann | Director | 231,145 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Paul JDiaz | $688.64K | -$7.78M | $2.86M | $31 | $125 |
| FY2025 Samraat S.Raha | $5.69M | $2.52M | $2.86M | $31 | $125 |
| FY2024 | $13.63M | $7.21M | $3.48M | $69 | $93 |
| FY2024 Paul JDiaz | $13.63M | $7.21M | $3.48M | $69 | $93 |
| FY2023 | $12.11M | $14.20M | $4.14M | $97 | $94 |
| FY2023 Paul JDiaz | $12.11M | $14.20M | $4.14M | $97 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 2,700 full-time equivalent employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 2, 2021 | Late filing | Notification of late filing |
| Oct 15, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 1, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 14, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 1, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 9, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 28, 2014 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 3, 2011 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 7, 2009 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 14, 2006 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 25, 2005 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |